Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Accumulated Expenses: 2011-2025

Historic Accumulated Expenses for Adma Biologics (ADMA) over the last 11 years, with Sep 2025 value amounting to $28.8 million.

  • Adma Biologics' Accumulated Expenses rose 4.69% to $28.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.8 million, marking a year-over-year increase of 4.69%. This contributed to the annual value of $34.1 million for FY2024, which is 3.60% up from last year.
  • Latest data reveals that Adma Biologics reported Accumulated Expenses of $28.8 million as of Q3 2025, which was down 34.34% from $43.9 million recorded in Q2 2025.
  • Adma Biologics' Accumulated Expenses' 5-year high stood at $43.9 million during Q2 2025, with a 5-year trough of $8.6 million in Q1 2021.
  • Moreover, its 3-year median value for Accumulated Expenses was $29.9 million (2023), whereas its average is $31.0 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 105.79% in 2021, then declined by 7.80% in 2024.
  • Adma Biologics' Accumulated Expenses (Quarterly) stood at $17.2 million in 2021, then skyrocketed by 45.16% to $25.0 million in 2022, then soared by 31.73% to $32.9 million in 2023, then increased by 3.60% to $34.1 million in 2024, then climbed by 4.69% to $28.8 million in 2025.
  • Its last three reported values are $28.8 million in Q3 2025, $43.9 million for Q2 2025, and $31.6 million during Q1 2025.